According to Silo Pharma, the US Patent and Trademark Office (USPTO) has indicated that it will issue a new patent on March 4, 2025 that will provide protection for Silo’s SPC-15 intranasal ketamine. The company says that the expected patent number for the patent titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females” is 12,239,614. Silo notes that the new patent includes new claims added to a 2022 patent (11,491,120) with the same title.
Columbia University developed the nasal formulation for Silo under a sponsored research agreement, which Silo announced in 2023. Later that year, Silo said that it had licensed soft mist spray technology from Medspray Pharma for delivery of SPC-15, and in September 2024, the company announced that it had completed a pre-IND meeting with the FDA regarding SPC-15 PTSD and stress-induced anxiety.
Silo CEO Eric Weisblum commented, “Strategic IP and patent expansion is key to advancing our lead asset SPC-15 to clinical trials and creating value for our full pipeline of novel assets. This new patent further supports our collaborative research with Columbia University and expands coverage for SPC-15.”
Read the Silo Pharma press release
